Could a cancer drug help lung damage after transplant?

NCT ID NCT03674047

Ongoing Disease control Sponsor: Massachusetts General Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 study tests the drug ruxolitinib (Jakafi) in 50 people who developed bronchiolitis obliterans syndrome (BOS) after a stem cell transplant. BOS is a serious lung condition that causes scarring and breathing problems. The goal is to see if ruxolitinib can improve lung function and control the disease by reducing inflammation.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ruxolitinib (also known as Jakafi)
What this could lead to: If successful, this could offer a new treatment option to improve lung function and slow disease progression in patients with bronchiolitis obliterans syndrome after transplant.
What could go wrong: This is a small, early-phase study with only 50 participants. The drug may not work for everyone, and side effects like infection or blood issues are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRONCHIOLITIS OBLITERANS SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bronchiolitis obliterans syndrome cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OTHER CANCER

Contacts and locations

Locations

City of Hope Cancer Center

Duarte, California, 91010, United States
Cleveland Clinic

Cleveland, Ohio, 44195, United States
Fred Hutchinson Cancer Center

Seattle, Washington, 98109, United States
H. Lee Moffitt Cancer Center

Tampa, Florida, 33612, United States
Huntsman Cancer Institute

Salt Lake City, Utah, 84112, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
Medical College of Wisconsin

Milwaukee, Wisconsin, 53226, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.